COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of ...

A phase 3 trial determined that Tivdak showed “game-changing results” for certain patients with cervical cancer, an expert told CURE®. Treatment with Tivdak (tisotumab vedotin) has been shown to ...

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics ...

A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Genmab A/S and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer ...

Better care for cancer patients may be on the horizon. A new prescription medicine for treating cervical cancer has been showing positive results in clinical trials. In phase 3 global trials, TIVDAK ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As the Federal Trade Commission (FTC) scrutinizes Pfizer’s $43 billion Seagen buyout, the antibody-drug conjugate (ADC) specialist has notched a phase 3 win that could broaden its cervical cancer ...

“TIVDAK is the only U.S. Food and Drug Administration-approved therapy in second-line recurrent or metastatic cervical cancer regardless of biomarker status, tumor histology and prior therapy,” said ...

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - TIVDAK is the first antibody-drug ...